Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Express Scripts
Fish and Richardson
Johnson and Johnson
Cantor Fitzgerald

Generated: July 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201657

« Back to Dashboard
NDA 201657 describes PARICALCITOL, which is a drug marketed by Sandoz Inc, Eci Pharms Llc, Dr Reddys Labs Ltd, Hikma Pharms, Rising Pharms Inc, Amneal Pharms, Teva Pharms Usa, Bionpharma Inc, Marksans Pharma, Hospira Inc, Aurobindo Pharma Ltd, Accord Hlthcare, and Amneal Pharms Co, and is included in fourteen NDAs. It is available from fifteen suppliers. Additional details are available on the PARICALCITOL profile page.

The generic ingredient in PARICALCITOL is paricalcitol. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the paricalcitol profile page.

Summary for NDA: 201657

Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 201657


Suppliers and Packaging for NDA: 201657

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SOLUTION;INTRAVENOUS 201657 NDA Hospira, Inc. 0409-1007 0409-1007-01 25 VIAL, MULTI-DOSE in 1 CARTON (0409-1007-01) > 1 mL in 1 VIAL, MULTI-DOSE (0409-1007-11)
SOLUTION;INTRAVENOUS 201657 NDA Hospira, Inc. 0409-1008 0409-1008-01 25 VIAL, MULTI-DOSE in 1 CARTON (0409-1008-01) > 1 mL in 1 VIAL, MULTI-DOSE (0409-1008-11)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength0.002MG/ML (0.002MG/ML)
Approval Date:Oct 21, 2014TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength0.005MG/ML (0.005MG/ML)
Approval Date:Oct 21, 2014TE:APRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength0.01MG/2ML (0.005MG/ML)
Approval Date:Oct 21, 2014TE:APRLD:No

Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
Queensland Health
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus